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Background
Intravenous Immunoglobulin (IVIG) is widely used in
paediatric inflammatory disease. The Department of
Health, UK recently produced guidelines for IVIG use and
a demand management plan in response to global IVIG
shortages, recommending use in "selected" patients with
juvenile dermatomyositis (JDMS), as a "last resort" in sys-
temic juvenile idiopathic arthritis (sJIA), and use not sup-
ported in juvenile systemic lupus erythematous (jSLE)
and vasculitis.
In this context, we have retrospectively audited use of IVIG
in a UK centre.
Materials and methods
A pilot analysis of children treated with IVIG in the previ-
ous 2 years.
Results
4 patients were male and 6 were female. The diseases
were: sJIA (4), JDMS (3), jSLE (1) and polyarteritis nodosa
(2). This represented approximately 50% of the total sJIA
cohort and 75% of the JDMS cohort presenting during the
study period.
9/10 had inadequate response to high dose pulse intrave-
nous and oral steroid therapy along with first line disease
modifying agents. The other patient received IVIG post
stem cell transplant for sJIA.
7 children were able to taper their prednisolone dose < 0.5
mg/k/day at the end of 6 months. This steroid sparing
effect is a surrogate marker for clinical response. One child
did not tolerate IVIG.
Conclusion
IVIG is a valuable adjunct in a broad spectrum of paediat-
ric inflammatory disease and we believe it should remain
a treatment option in selected cases with partial response
to standard first line therapies.
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